CORT (Corcept Therapeutics) Long-Term Debt: $0.0 Mil (As of Mar. 2026)


CORT Corcept Therapeutics Inc CORT
88 GF Score
Price $88.48
GF Value $62.12
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Long-Term Debt?

Corcept Therapeutics CORT +1.76% 88 Long-Term Debt is $0.0 Mil as of Mar. 2026. GuruFocus rates CORT with a GF Score™ of 88/100 and a GF Value™ of $62.12 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Corcept Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.0 Mil.

Corcept Therapeutics  (NAS:CORT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Corcept Therapeutics Long-Term Debt Related Terms

Corcept Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Long-Term Debt Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CORT
88GF Score
Corcept Therapeutics Inc CORT
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.0 Mil mean?
Corcept Therapeutics (CORT) has a Long-Term Debt of $0.0 Mil as of Mar. 2026.
Is Corcept Therapeutics' Long-Term Debt too high?
Corcept Therapeutics' current Long-Term Debt is $0.0 Mil. Overall, Corcept Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Long-Term Debt compare to PRAX and IBRX?
Corcept Therapeutics' Long-Term Debt of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Corcept Therapeutics's current Long-Term Debt is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $62.12, compared to a current price of $88.48 — trading 42.4% above its estimated fair value. The current Long-Term Debt is $0.0 Mil. Corcept Therapeutics' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current Long-Term Debt is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (CORT) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of $88.48 is trading 42.4% above its estimated GF Value™ of $62.12. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for CORT:

  • Long-Term Debt: $0.0 Mil
  • GF Value™: $62.12 vs. price of $88.48 (42.4% above fair value)
  • GF Score™: 88/100 with 8 warning signs

No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
88GF Score

Get the complete analysis for CORT

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$88.48
Price
$62.12
GF Value